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Bhautesh Dinesh Jani1, Jonathan Cavanagh2, Sarah JE Barry3, Geoff Der4, Naveed Sattar5 and Frances S Mair6*Abstract
Background: Depression is common in patients with cardiometabolic diseases but little is known about the
relationship, if any, between cardiovascular risk factor values and depressive symptoms in patients with these
conditions. The objective of this paper is to study the association between cardiovascular risk factors and
concurrent depressive symptoms in patients with three common cardiometabolic conditions: coronary heart
disease (CHD), stroke and diabetes.
Methods: We retrospectively reviewed primary care data for N = 35537 with 1 of the above 3 conditions who
underwent depression screening using the depressive subscale of hospital anxiety and depression score (HADS-D). We
reviewed 4 cardiometabolic risk factors (Systolic Blood Pressure [SBP], Diastolic Blood Pressure [DBP], BMI and total
cholesterol) recorded concurrently in all patients and HbA1c in patients with diabetes (n = 18453). We analysed the
association between individual risk factor value and a positive HADS-D screening result (>7) using logistic regression.
Results: SBP and BMI were noted to have a non-linear “J-shaped” relationship with the probability of having a positive
HADS-D and observed nadirs (levels with the lowest probability) of 148 mm Hg and 30.70 kg/m2, respectively. Total
cholesterol and DBP found to have a weaker curvilinear association with concurrent depression symptoms and nadirs
of 3.60 mmol/l and 74 mmHg. Among patients with Diabetes, HbA1c was also found to have a “J-shaped” relationship
with probability of having a positive HADS-D with an observed nadir of 7.06% DCCT. The above relationships remain
significant after adjusting for age, sex, socio-economic status and number of co-morbid conditions.
Conclusion: In patients with cardiometabolic disease, cardiovascular risk factor values at both extremes were
associated with higher positive depression screening after adjusting for confounders. These findings have potentially
important implications for clinical practice in relation to both risk stratification for depression and approaches to
secondary prevention in individuals with cardiometabolic disease and merit further investigation to determine the
nature and direction of the observed association.
Please see related article: http://www.biomedcentral.com/1741-7015/12/199.
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Patients with chronic disease are two to three times
more likely to suffer from depression when compared to
the general population [1,2]. It is estimated that depression
prevalence is 15-25% in patients with cardio-metabolic
diseases such as coronary heart disease (CHD), diabetes
and stroke [3-5]. Those with cardiometabolic disease who
have suffered from depression have been reported to ex-
perience increased adverse clinical outcomes and mortal-
ity, and poorer functional abilities [4,6-8].
In 2008, the American Heart Association Science Ad-
visory recommended routine depression screening for all
patients with CHD [9]. However, there is no evidence to
date that routine depression screening for patients with
cardiometabolic disease leads to any improvement in de-
pression or cardiac outcomes [10,11]. Moreover, there is
some evidence in the UK and US to suggest that routine
depression screening for all patients with cardiometa-
bolic disease may struggle to achieve universal coverage
[12-14]. In the UK, NICE(National Institute for Health
and Care Excellence) recommends that depression screen-
ing or ‘case finding’ in patients with chronic disease should
be targeted towards those who are believed to be ‘high
risk’ [15]; but further research is needed to define who is
at ‘high risk’.
The relationship between depression and traditional
cardiometabolic disease risk factors such as obesity, hyper-
tension, hyperlipidaemia and raised HbA1c have been
studied extensively in the general population. Depression
is noted to have a significant positive association with
obesity in the general population, with a stronger associ-
ation noted in females [16,17]. In addition, evidence from
longitudinal studies show that depression may have a bi-
directional relationship with obesity [18]. Results from a
meta-analysis of prospective cohort studies shows that de-
pression increases the risk of hypertension incidence in
the community [19]. A contradictory relationship has been
observed between depression and hyperlipidaemia in eld-
erly men and women in the community; with increased
prevalence of depressive symptoms observed with low
levels of high density lipoprotein cholesterol (higher
atherogenic risk) in women and with low levels of low
density lipoprotein cholesterol (lower atherogenic risk) in
men [20]. In a prospective study of older adults in the gen-
eral population, the probability of depression increased
with raised HbA1c [21]. However, most of the evidence in
this area has come from general population studies and
there is a paucity of research in those with known cardio-
metabolic diseases who are likely to be subjected to treat-
ment to reduce these risk factors.
Little is known about the relationship between cardio-
vascular risk factors and depressive symptoms in those
with cardiometabolic disease. The aim of this project is
to address this gap by studying the relationship, if any,between a range of cardiovascular risk factors (specific-
ally SBP, DBP, total cholesterol, HbA1c and BMI) and
depressive symptoms in those with three cardiometa-
bolic conditions, namely, stroke, diabetes and CHD.
Methods
Ethics statement
We received approval from the West of Scotland re-
search ethics committee to undertake this work. The
work involved retrospective analysis of a large routinely
collected dataset which was completely annonymised
and the research team did not have access to patient
identifiers, hence individual patient consent was not ob-
tained. NHS Greater Glasgow and Clyde Enhanced Ser-
vices data group, which was the authorised “guardian” of
this data set, granted the permission to analyse the data.
Study design and setting
The data reported in this paper comes from the West of
Scotland, with a population of circa 1.8 million served
by two different health boards. The local health boards
oversee a programme of incentivised depression screen-
ing in chronic disease as part of a wider chronic disease
management programme of ‘Local Enhanced Services’
(LES). These are contractual arrangements at a local
health board level with family practices where incentivi-
sation is offered to primary care practitioners on certain
indicators of chronic disease management. However,
there are no penalties for non-adherence. In the areas
under investigation in our study, family practices were
paid under the LES scheme to carry out a comprehensive
annual health assessment, which included depression
screening, for patients with three common cardiometa-
bolic conditions, CHD, diabetes and stroke. The annual
health assessment was usually carried out by a practice
nurse and lasted approximately one hour. The protocol
for health assessment was specific for each of the three
diseases but included monitoring of blood pressure (BP),
total cholesterol, body mass index (BMI) and in those with
diabetes, HbA1c. The assessment included detailed history
taking, various physical examinations and blood tests.
Participants
We restricted our analysis to adults aged from 18 to 90
and health assessments recorded between 01/04/2008 to
31/03/2009. A total of 125,143 patients were listed as
having CHD, diabetes or stroke in the year 2008–09, the
“DepChron” dataset [14], described in a previous publi-
cation. Of the total sample, 10,670 (8.5%) patients were
under treatment for depression and were thus exempt
from screening. The remaining 114,473 (91.5% of total
sample size) patients were eligible for depression screen-
ing. However, the uptake of depression screening was
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gible) and 78,936 (68.9%) were not screened.Measurement of clinical risk factors and outcome variable
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) measurements were recorded in mm Hg and
BMI in kg/m2 determined from height and weight mea-
surements. A blood sample was collected by the practice
nurse at the time of assessment; the result for total chol-
esterol was reported in mmol/l and HbA1c was reported
in Diabetes Control and Complications Trial (DCCT)
units.
We restricted the values for cardiovascular risk factors
to a clinically plausible range based on both our clinical
judgement and the findings of general population stud-
ies. SBP measurements were restricted to a range be-
tween 90 to 240 mm Hg and DBP to a range between 50
to 130 mm Hg [22,23]. Similarly, BMI was restricted to a
range between 15 to55 [24], total cholesterol to 2–10
[25] and HbA1C to 3-18% [26]. Observations in the data
which were outside these range were excluded from the
analysis. The depression subscale of HADS (HADS-D)
gives a total score of 0 to 21, and a threshold of >7 was
used to define the presence of depressive symptoms, as
endorsed by national guidelines [27]. The area based
Scottish Index of Multiple Deprivations (SIMD) was
used as a measure of socioeconomic status [28].Statistical analysis
We used multiple logistic regression with the outcome
variable as the prevalence of a positive screening for de-
pression (defined as HADS-D >7). We used five separate
regression models to examine the impact of each indi-
vidual cardiovascular risk factor (SBP, DBP, total choles-
terol, BMI, HbA1c) on the odds of a raised HADS-D.
We entered quadratic terms for each clinical measure
into regression models to allow for a non-linear relation-
ship. We entered age (18–64 vs. 65–90), sex (male vs. fe-
male) and socio-economic status (deprived: SIMD deciles
1–5 vs. affluent: SIMD deciles 6–10) into all of the models
as binary variables. We also included the number of co-
morbid conditions (range 1–3, representing a combin-
ation of one or more of the three cardiometabolic disease
under investigations: CHD, stroke or diabetes) into all re-
gression models as a categorical variable. We present the
results as a graph of the predicted probability of a raised
HADS-D against corresponding values of the clinical risk
factor. We calculated the turning point for each risk fac-
tor using the formula min = −b/2a where “a” represents
coefficient of quadratic term and “b” represents coeffi-
cient of linear term.
We used the R statistical software, version 3.0.2 for
statistical analysis [29].Supplementary and sensitivity analyses
The screened population was a subset of the whole data-
set and the majority of the patients eligible for depres-
sion screening did not have HADS-D recorded due to
poor uptake of depression screening. We compared the
demographic features and distribution of clinical risk
factors in both the screened population and the total
population. We tested for interactions of each clinical
risk factor with age, gender, number of comorbid condi-
tion and deprivation status for each of the corresponding
regression models to check for potential effect modifica-
tion. We also tested for cubic terms in each of the five
regression models for five clinical measures. Sensitivity
of the results to excluded values was assessed by repeat-
ing the analyses with all available patients.
We also performed multiple linear regression analysis
with HADS-D as a continuous scale. We used five separ-
ate regression models to examine the impact of each
individual cardiovascular risk factor (SBP, DBP, total
cholesterol, BMI, HbA1c) on HADS-D as a continuous
scale after excluding extreme values for each clinical
measure as defined above. Quadratic and cubic terms
for each clinical measure and other predictor variables,
such as age, sex, socio-economic status and number of
co-morbid conditions were added to the linear regres-
sion model as described above. The turning point or the
“nadir” was calculated using the same formula described
in the preceding section.
Results
Sample size and characteristics
N= 35,537 (32.5% of total population) patients with one of
the three chronic cardiometabolic diseases CHD, previous
stroke and diabetes had results of depression screening
with HADS-D recorded (see Figure 1). The demographic
characteristics and cardiovascular risk factor distribution
between the screened and total population were similar
(please see “Additional file 1-Additional Analysis”). The
HADS-D was positive (>7) for 7080 patients (19.9%). The
demographic characteristics of the study sample are de-
scribed in Table 1.
The distributions of the five cardiovascular risk factors
in the study sample such as sample mean, standard devi-
ation, missing values and the observations outside the
plausible range considered and observed nadirs are de-
scribed in Table 2.
Blood pressure, total cholesterol, body mass index
and depression
SBP was found to have a “J-shaped” relationship with
the probability of having a positive result with HADS-D
screening, based on a regression model using all of the
screened population with at least one of the three chronic
diseases. The nadir or the minimum level of SBP with the
Figure 1 Study sample size and recruitment.
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HADS-D was found to be 148 mm Hg (see Figure 2). DBP
was found to have a “J-shaped” relationship with the prob-
ability of having a positive result with HADS-D screening,
based on a regression model using all of the screened
population with at least one of the three chronic diseases.
However, the shape of the J-curve was shallow for DBP
when compared with SBP. The nadir for DBP with the
least probability of having a positive screening result with
HADS-D was found to be 74 mm Hg. This observed rela-
tionship between SBP, DBP and depressive symptoms
remained significant after adjusting for age, sex, number
of comorbid conditions and socio-economic status.
BMI was found to have a non-linear relationship with
the probability of having a positive result with HADS-D
screening, based on a regression model using all of the
screened population with at least one of the three cardio-
metabolic conditions. The nadir or the minimum level for
BMI was found to be 30.70 kg/m2 (see Figure 2). Total
Cholesterol was found to have a non-linear relationshipTable 1 Patient demographics of the study sample
Demographics DepChron
(n=35,537)
Age group Missing 11
18-64 11553 (32.52%)
64-90 23973 (67.48%)
Gender Missing 18
Male 20658 (58.16%)
Female 14861 (41.84%)
Deprivation status Missing 732
Deprived 22726 (65.30%)
Affluent 12079 (34.70%)
Number of comorbid condition Missing 0
One 27356 (76.99%)
Two 7410 (20.85%)
Three 771 (2.16%)with the probability of having a positive result with
HADS-D screening (HADS-D > 7), based on the same re-
gression model described above. However, the shape of
the curve was less pronounced with lower values of total
cholesterol and wider confidence intervals when com-
pared to SBP and BMI. The nadir or the minimum level
for total cholesterol was found to be 3.60 mmol/l (see
Figure 2). The relationship between BMI and total choles-
terol with probability of having HADS-D positive re-
mained significant after adjusting for age, sex, number of
comorbid conditions and socio-economic status.
HbA1C and depression
HbA1c was found to have a non-linear “J-shaped” re-
lationship with the probability of having a positive re-
sult with HADS-D screening (HADS-D > 7), based on
a regression model using only patients with diabetes
(n = 18,453, missing = 2775, excluded = 2). The shape of
the curve was more similar but the confidence intervals
were slightly wider, when compared to SBP, DBP and BMI.
The nadir or the minimum level for HbA1c was found to
7.06% DCCT (54 mmol/mol IFCC) (see Figure 3). This re-
lationship also remained significant after adjusting for age,
sex, number of comorbid conditions and socio-economic
status.
Supplementary and sensitivity analysis
There were no significant cubic terms for any of the car-
diovascular risk factors. There were significant interac-
tions between DBP and sex (p-value = 0.01) and BMI
and age (p-value = 0.009) (please see “Additional file 1-
Additional Analysis”). Hence, we calculated the nadirs
separately for these groups with significant interactions.
The nadirs for DBP were 78 mm Hg for males and
63 mm Hg for females respectively. The nadirs for BMI
were 32.12 kg/m2 for those aged18-64 years and
29.54 kg/m2 for those 65–90 years respectively. The
shape of the curve was unchanged for DBP and BMI
after doing sub-group analysis for sex and age respect-
ively (please see “Additional file 1-Additional Analysis”).
The results were unchanged after including extremes of
clinical values outside the clinically plausible range de-
scribed above (please see “Additional file 1-Additional
Analysis”).
The five cardiovascular risk factors had a non-linear
relationship in the respective linear regression models,
after adjusting for age, sex, socio-economic status and
number of co-morbid conditions. The observed nadirs
for SBP, DBP, total cholesterol and BMI were 145 mm
Hg, 78 mm Hg, 3.41 mmol/l and 30.25 kg/m2 respect-
ively. The observed nadir for HbA1c in patients with
diabetes was 6.21 DCCT (44.4 mmol/mol IFCC). The
value for HADS-D increased with increase in value of
these clinical measures above their respective nadirs but
Table 2 Study sample (n = 35537) distribution for the five clinical risk factors, missing values, the number of extreme
observations outside the usually observed clinically plausible values, analyzed data and observed nadirs
Clinical measure (range included) Mean (SD) N missing Exclusions N analyzed Observed nadirs
Systolic BP (90–240) 133 (17.54) 3398 n <90 = 110 32029 148 mm Hg
n >240 = 0
Diastolic BP (50–130) 74 · 57 (10.32) 3398 n <50 = 165 31972 74 mm Hg
n >130 = 2
Body mass index (15–55) 28 · 95 (6.02) 5398 n <15 = 29 30042 30.70 kg/m2
n >55 = 68
Total cholesterol (2–10) 4 · 31 (1.05) 4226 n <2 = 50 31244 3.60 mmol/l
n >10 = 17
HbA1c (3–18) 7 · 52 (1.68) 2775 n <3 = 2 15676 7.06 DCCT
n >18 = 0
Legend: BP = Blood Pressure; n = 18453 for HbA1c.
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nadirs. There were no significant cubic terms. The re-
sults of each linear regression are presented in detail in
“Additional file 2- Linear Regression with HADS-D as
continuous measure”.
Discussion
In a large, community based sample of patients with
CHD, previous stroke, or diabetes depressive symptoms
assessed using depression screening were found to have
a nonlinear association with five routine cardiovascular
risk factors of disease management. The relationships
were ‘J-shaped’ with high levels of SBP and BMI associ-
ated with greater levels of concurrent depressive symp-
toms, but with the lowest levels also associated with
increased prevalence of depressive symptoms. DBP and
total Cholesterol had a similar but weaker relationship
with depression. In patients with diabetes, a “J-shaped”
relationship was again observed between HbA1c levels
and depressive symptoms. These associations remained
significant after adjusting for demographic factors suchFigure 2 Relationship of Systolic BP (SBP), Diastolic BP (DBP), Body M
positive HADS-D (>7) with 95% confidence intervals.as age, sex, number of comorbid conditions and socio-
economic status; including or excluding clinical obser-
vations with extreme values and using HADS-D as
continuous scale.
Previous evidence studying the relationship between
cardiovascular risk factor values and depressive symp-
toms has mainly come from general population studies.
Barrett-Connor et al. reported a non-linear relationship
between DBP and depression with a observed nadir of
75 mm Hg DBP for concurrent depressive symptoms in a
general population sample [30]. In various cross-sectional
studies involving mainly elderly population, depression
has been observed to have a non-linear association with
SBP [31-34] and DBP [30,35]. Similarly, increased preva-
lence of depressive symptoms has been observed with ex-
treme values of total cholesterol [36,37] and HbA1c in
general population samples [38], in a non-linear trend.
There is as yet no published literature that we know of
that examines the relationship between cardiovascular risk
factors and depressive symptoms in those with cardiomet-
abolic disease.ass Index (BMI) and total cholesterol with probability of having a
Figure 3 Relationship of HbA1C with probability of having a
positive HADS-D (>7) with 95% confidence intervals.
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SBP, DBP, BMI and HbA1c and adverse clinical out-
comes such as increased incidence of vascular events
and deaths in patients with cardiometabolic conditions
has been reported extensively [39-43].
There are two potential implications of our findings.
Firstly, if the association between extreme values of
these risk factors with depressive symptoms in those
with cardiometabolic disease is supported by prospective
studies, then this relationship could be used to identify
those at “high risk” of depression. This would then offer
a mechanism for targeting of depression screening in
those with cardiometabolic disease. Secondly, these re-
sults need to be replicated using other datasets and also
prospectively to further explain the nature and direction
of the observed association between depressive symp-
toms and cardiovascular risk factors values. Such further
investigation is necessary in order to determine whether
the lower cardiovascular risk factors are merely markers
of other disease processes (for example, low total choles-
terol levels associated with malnutrition, liver diseases
and haematological diseases) [44-46] that may make pa-
tients more vulnerable to experiencing depressive symp-
toms or whether it could be attributed to a potential
side-effect of aggressive cardiovascular risk factor man-
agement [47-50].
This study has a number of key strengths. The data came
from a large, community based sample, and importantlyreflecting real life clinical practice. There are several
limitations. As the study was based on cross-sectional
analysis, it is not possible to make causal inferences
from the findings of this study. It is therefore unclear
whether the observed non-linear association of cardio-
vascular risk factors with prevalent depressive symptoms
is due to cause or effect.
Secondly, we did not have complete information on
biobehavioural factors such as smoking status, alcohol
intake and levels of physical activity which are likely
to influence the values of cardiovascular risk factors
considered and also the prevalence of depressive
symptoms [51-54].
Since only a minority of the patients were actually
screened, depression status was unknown for a large
number of patients, which remains an important limita-
tion. There may be important differences between pa-
tients with known depression status and those whose
depression status was unknown, which are not clearly
evident from their baseline demographic data. Practi-
tioners may intuitively screen those patients where they
are more likely to get a positive result, for instance pa-
tients with multimorbidity. Also, there is a possibility of
reverse causality with GPs reviewing a patient whom
they consider to have depression and offering screening
subsequently. Previously reported barriers to discussing
depression (or mental health) in patients with chronic
disease in primary care, such as stigma associated
around the ‘label’ and physicians’ preconception of nor-
malizing depression in patients with chronic disease,
could be influencing factors behind low uptake of de-
pression screening in our study [55,56].
Finally, the overall accuracy of depression screening in
our study was reliant on HADS-D which is a self-reported
measure and it is not a gold standard measure for asses-
sing depressive symptoms in patients with cardiometabolic
disease in a primary care setting [11,57,58]. We also did
not have information on history of previous episodes of
depression for patients in our study which may influence
the prevalence levels for depressive symptoms.Conclusion
In a general practice sample of patients with CHD,
stroke, or diabetes, depressive symptoms were found to
have a strong curvilinear association with SBP, BMI, and
HbA1c; and a weaker curvilinear association with total
cholesterol and DBP. Further investigation of these rela-
tionships is urgently needed to clarify the nature of these
associations, in order to determine whether they have
potentially important implications for clinical practice in
relation to either risk stratification for depression or our
approach to secondary prevention in individuals with
cardiometabolic disease.
Jani et al. BMC Cardiovascular Disorders 2014, 14:139 Page 7 of 8
http://www.biomedcentral.com/1471-2261/14/139Additional files
Additional file 1: “Additional Analysis”. Results of sensitivity and
supplementary analysi.
Additional file 2: “Linear Regression with HADS-D as continuous
measure”. Results of statistical analysis with linear regression models
using HADS-D as a continuous measure.
Competing interests
The authors declared that they have no competing interests.
Author contributions
BDJ, JC, NS, SB and FSM designed the study and obtained the funding. BDJ,
SB and GD analysed the data. All authors interpreted the findings and
contributed to the drafting of this paper. FSM is the guarantor and the lead
author for this manuscript. All authors read and approved the final
manuscript.
Acknowledgement
The study was funded by Chief Scientist Office, Scotland CAF/12/04. The
funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Author details
1CSO Clinical Fellow, General Practice and Primary Care, Institute of Health
and Wellbeing, College of Medical, Veterinary and Life Sciences, University of
Glasgow, Glasgow G12 9LX, UK. 2Professor of Psychiatry, Mental Health and
Wellbeing, Sackler Institute, Institute of Health and Wellbeing, College of
Medical, Veterinary and Life Sciences, University of Glasgow, Neurology Block,
Southern General Hospital, Glasgow G51 4TF, UK. 3Consultant Biostatistician,
Robertson Centre for Biostatistics, Institute of Health and Well Being, College
of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12
8QQ, UK. 4Statistician, MRC/CSO Social and Public Health Sciences Unit,
Institute of Health and Wellbeing, College of Medical, Veterinary and Life
Sciences, University of Glasgow, Glasgow G12 8RZ, UK. 5Professor of
Metabolic Medicine, BHF Glasgow Cardiovascular Research Centre, Institute
of Cardiovascular and Medical Sciences, College of Medical, Veterinary and
Life Sciences, University of Glasgow, Glasgow G12 8TA, UK. 6Professor of
Primary Care Research, General Practice and Primary Care, Institute of Health
and Wellbeing, College of Medical, Veterinary and Life Sciences, University of
Glasgow, Glasgow G112 9LX, UK.
Received: 24 July 2014 Accepted: 3 October 2014
Published: 28 October 2014
References
1. Egede LE: Major depression in individuals with chronic medical
disorders: prevalence, correlates and association with health resource
utilization, lost productivity and functional disability. Gen Hosp Psychiatry
2007, 29:409–416.
2. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B: Depression,
chronic diseases, and decrements in health: results from the World
Health Surveys. Lancet 2007, 370:851–858.
3. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K: The prevalence of
co-morbid depression in adults with Type 2 diabetes: a systematic
review and meta-analysis. Diabet Med 2006, 23:1165–1173.
4. Hadidi N, Treat-Jacobson DJ, Lindquist R: Poststroke depression and functional
outcome: a critical review of literature. Hear Lung 2009, 38:151–162.
5. Whooley MA, De JP, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray
S, Na B, Feldman MD, Schiller NB, Browner WS: Depressive symptoms,
health behaviors, and risk of cardiovascular events in patients with
coronary heart disease. JAMA 2008, 300:2379–2388.
6. Larsen KK, Christensen B, Sondergaard J, Vestergaard M: Depressive
Symptoms and Risk of New Cardiovascular Events or Death in Patients
with Myocardial Infarction: A Population-Based Longitudinal Study
Examining Health Behaviors and Health Care Interventions. PLoS One
2013, 8:e74393.
7. Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, Kinder L,
Young B, Von KM: The association of comorbid depression with mortality
in patients with type 2 diabetes. Diabetes Care 2005, 28:2668–2672.8. Pozuelo L, Tesar G, Zhang J, Penn M, Franco K, Jiang W: Depression and
heart disease: what do we know, and where are we headed? Cleve Clin J
Med 2009, 76:59–70.
9. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG,
Lespérance F, Mark DB, Sheps DS, Taylor CB, Froelicher ES: Depression and
coronary heart disease: recommendations for screening, referral, and
treatment. Circulation 2008, 118:1768–1775.
10. Ontario HQ: Screening and management of depression for adults with
chronic diseases: an evidence-based analysis. Ont Health Technol Assess
Ser 2013, 13:1–45.
11. Thombs BD, Roseman M, Coyne JC, de Jonge P, Delisle VC, Arthurs E, Levis
B, Ziegelstein RC: Does Evidence Support the American Heart
Association’s Recommendation to Screen Patients for Depression in
Cardiovascular Care? An Updated Systematic Review. PLoS One 2013,
8:e52654.
12. Smolderen KG, Buchanan DM, Amin AA, Gosch K, Nugent K, Riggs L, Seavey
G, Spertus JA: Real-world lessons from the implementation of a
depression screening protocol in acute myocardial infarction patients:
implications for the American Heart Association depression screening
advisory. Circ Qual Outcomes 2011, 4:283–292.
13. Burton C, Simpson C, Anderson N: Diagnosis and treatment of depression
following routine screening in patients with coronary heart disease or
diabetes: a database cohort study. Psychol Med 2013, 43:529–537.
14. Jani BD, Purves D, Barry S, Cavanagh J, McLean G, Mair FS: Challenges and
Implications of Routine Depression Screening for Depression in Chronic
Disease and Multimorbidity: A Cross Sectional Study. PLoS One 2013,
8:e74610.
15. NICE: Depression in Adults with a Chronic Physical Health Problem: Treatment
and Management; 2009.
16. Scott KM, Bruffaerts R, Simon GE, Alonso J, Angermeyer M, de Girolamo G,
Demyttenaere K, Gasquet I, Haro JM, Karam E, Kessler RC, Levinson D,
Medina Mora ME, Oakley Browne MA, Ormel J, Villa JP, Uda H, Von Korff M:
Obesity and mental disorders in the general population: results from the
world mental health surveys. Int J Obes (Lond) 2008, 32:192–200.
17. De Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P:
Depression and obesity: A meta-analysis of community-based studies.
Psychiatry Res 2010, 178:230–235.
18. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BWJH,
Zitman FG: Overweight, obesity, and depression: a systematic review and
meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010,
67:220–229.
19. Meng L, Chen D, Yang Y, Zheng Y, Hui R: Depression increases the risk of
hypertension incidence: a meta-analysis of prospective cohort studies.
J Hypertens 2012, 30:842–851.
20. Ancelin ML, Carrire I, Boulenger JP, Malafosse A, Stewart R, Cristol JP, Ritchie
K, Chaudieu I, Dupuy AM: Gender and genotype modulation of the
association between lipid levels and depressive symptomatology in
community-dwelling elderly (The ESPRIT Study). Biol Psychiatry 2010,
68:125–132.
21. Hamer M, Batty GD, Kivimaki M: Haemoglobin A1c, fasting glucose and
future risk of elevated depressive symptoms over 2 years of follow-up in
the English Longitudinal Study of Ageing. Psychol Med 2011,
41:1889–1896.
22. Pater C: The Blood Pressure “Uncertainty Range” - a pragmatic approach
to overcome current diagnostic uncertainties (II). Curr Control Trials
Cardiovasc Med 2005, 6:5.
23. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H-W, Joffres M,
Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B,
Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence
and blood pressure levels in 6 European countries, Canada, and the
United States. JAMA 2003, 289:2363–2369.
24. Penman AD, Johnson WD: The changing shape of the body mass index
distribution curve in the population: implications for public health policy
to reduce the prevalence of adult obesity. Prev Chronic Dis 2006, 3:A74.
25. Thompson R, O’Regan C, Morant S, Phillips B, Ong S: Measurement of
baseline total cholesterol: new data from The Health Improvement
Network (THIN) database. Prim Care Cardiovasc J 2008, 1:107.
26. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole
CD: Survival as a function of HbA(1c) in people with type 2 diabetes: a
retrospective cohort study. Lancet 2010, 375:481–489.
27. NICE: Depression in Adults (update); 2009.
Jani et al. BMC Cardiovascular Disorders 2014, 14:139 Page 8 of 8
http://www.biomedcentral.com/1471-2261/14/13928. Scottish Index of Multiple Deprivation (SIMD). In http://www.scotland.gov.
uk/Topics/Statistics/SIMD.
29. Team RC: R Core Team (2012). R: A language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna,
Austria. In 2012. ISBN 3-900051-07-0. http://www.R-project.org/.
30. Barrett-Connor E, Palinkas LA: Low blood pressure and depression in older
men: a population based study. BMJ 1994, 308:446–449.
31. Stroup-Benham CA, Markides KS, Black SA, Goodwin JS: Relationship
between low blood pressure and depressive symptomatology in older
people. J Am Geriatr Soc 2000, 48:250–255.
32. Pilgrim JA, Stansfeld S, Marmot M: Low blood pressure, low mood? BMJ
1992, 304:75–78.
33. Niu K, Hozawa A, Awata S, Guo H, Kuriyama S, Seki T, Ohmori-Matsuda K,
Nakaya N, Ebihara S, Wang Y, Tsuji I, Nagatomi R: Home blood pressure is
associated with depressive symptoms in an elderly population aged
70 years and over: a population-based, cross-sectional analysis. Hypertens
Res 2008, 31:409–416.
34. Kim B-S, Bae JN, Cho MJ: Depressive symptoms in elderly adults with
hypotension: different associations with positive and negative affect.
J Affect Disord 2010, 127:359–364.
35. Jorm AF: Association of hypotension with positive and negative affect
and depressive symptoms in the elderly. Br J Psychiatry 2001,
178:553–555.
36. Morgan RE, Palinkas LA, Barrett-Connor EL, Wingard DL: Plasma cholesterol
and depressive symptoms in older men. Lancet 1993, 341:75–79.
37. Steegmans PH, Hoes AW, Bak AA, van der Does E, Grobbee DE: Higher
prevalence of depressive symptoms in middle-aged men with low serum
cholesterol levels. Psychosom Med 2000, 62:205–211.
38. Kivimaki M, Tabak AG, Batty GD, Singh-Manoux A, Jokela M, Akbaraly TN,
Witte DR, Brunner EJ, Marmot MG, Lawlor DA: Hyperglycemia, Type 2
Diabetes, and Depressive Symptoms: The British Whitehall II study.
Diabetes Care 2009, 32:1867–1869.
39. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP: What is the optimal
blood pressure in patients after acute coronary syndromes?: Relationship
of blood pressure and cardiovascular events in the PRavastatin OR
atorVastatin Evaluation and Infection Therapy-Thrombolysis In
Myocardial Infarction (PROVE IT-TI. Circulation 2010, 122:2142–2151.
40. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA,
Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA,
Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F: Effects of
intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med
2010, 362:1575–1585.
41. Messerli FH, Panjrath GS: The J-curve between blood pressure and coron-
ary artery disease or essential hypertension: exactly how essential? J Am
Coll Cardiol 2009, 54:1827–1834.
42. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG,
Mookadam F, Lopez-Jimenez F: Association of bodyweight with total
mortality and with cardiovascular events in coronary artery disease: a
systematic review of cohort studies. Lancet 2006, 368:666–678.
43. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman
WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG,
Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med 2008, 358:2545–2559.
44. Ghadir MR, Riahin AA, Havaspour A, Nooranipour M, Habibinejad AA: The
relationship between lipid profile and severity of liver damage in
cirrhotic patients. Hepat Mon 2010, 10:285–288.
45. Marini A, Carulli G, Azzarà A, Grassi B, Ambrogi F: Serum cholesterol and
triglycerides in hematological malignancies. Acta Haematol 1989, 81:75–79.
46. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Inverse association between
lipid levels and mortality in men with chronic kidney disease who are
not yet on dialysis: effects of case mix and the malnutrition-
inflammation-cachexia syndrome. J Am Soc Nephrol 2007, 18:304–311.
47. O’Neil A, Sanna L, Redlich C, Sanderson K, Jacka F, Williams LJ, Pasco JA,
Berk M: The impact of statins on psychological wellbeing: a systematic
review and meta-analysis. BMC Med 2012, 10:154.
48. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S:
Unintended effects of statins from observational studies in the general
population: systematic review and meta-analysis. BMC Med 2014, 12:51.
49. Zureik M, Courbon D, Ducimetière P: Serum cholesterol concentration and
death from suicide in men: Paris prospective study I. BMJ 1996,
313:649–651.50. Olson MB, Kelsey SF, Matthews KA, Bairey Merz CN, Eteiba W, McGorray SP,
Cornell CE, Vido DA, Muldoon MF: Lipid-lowering medication use and
aggression scores in women: a report from the NHLBI-sponsored WISE
study. J Womens Health (Larchmt) 2008, 17:187–194.
51. Sullivan LE, Fiellin DA, O’Connor PG: The prevalence and impact of alcohol
problems in major depression: a systematic review. Am J Med 2005,
118:330–341.
52. Van der Meer RM, Willemsen MC, Smit F, Cuijpers P: Smoking cessation
interventions for smokers with current or past depression. Cochrane
Database Syst Rev 2013, 8:CD006102.
53. Chaiton MO, Cohen JE, O’Loughlin J, Rehm J: A systematic review of
longitudinal studies on the association between depression and
smoking in adolescents. BMC Public Health 2009, 9:356.
54. Blumenthal JA, Babyak MA, Carney RM, Huber M, Saab PG, Burg MM, Sheps
D, Powell L, Taylor CB, Kaufmann PG: Exercise, depression, and mortality
after myocardial infarction in the ENRICHD trial. Med Sci Sports Exerc 2004,
36:746–755.
55. Karasz A, Dowrick C, Byng R, Buszewicz M, Ferri L, Olde Hartman TC, Van DS,
van Weel-Baumgarten E, Reeve J: What we talk about when we talk about
depression: doctor-patient conversations and treatment decision
outcomes. Br J Gen Pract 2012, 62:e55–e63.
56. Coventry PA, Hays R, Dickens C, Bundy C, Garrett C, Cherrington A, Chew-
Graham C: Talking about depression: a qualitative study of barriers to
managing depression in people with long term conditions in primary
care. BMC Fam Pract 2011, 12:10.
57. Haddad M, Walters P, Phillips R, Tsakok J, Williams P, Mann A, Tylee A:
Detecting Depression in Patients with Coronary Heart Disease: A
Diagnostic Evaluation of the PHQ-9 and HADS-D in Primary Care,
Findings From the UPBEAT-UK Study. PLoS One 2013, 8:e78493.
58. Meader N, Mitchell AJ, Chew-Graham C, Goldberg D, Rizzo M, Bird V, Kessler
D, Packham J, Haddad M, Pilling S: Case identification of depression in
patients with chronic physical health problems: a diagnostic accuracy
meta-analysis of 113 studies. Br J Gen Pract 2011, 61:e808–e820.
doi:10.1186/1471-2261-14-139
Cite this article as: Jani et al.: Revisiting the J shaped curve, exploring
the association between cardiovascular risk factors and concurrent
depressive symptoms in patients with cardiometabolic disease: Findings
from a large cross-sectional study. BMC Cardiovascular Disorders
2014 14:139.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
